Free Trial

Virax Biolabs Group (VRAX) Competitors

Virax Biolabs Group logo
$0.96 +0.04 (+4.41%)
Closing price 03:53 PM Eastern
Extended Trading
$0.95 -0.01 (-1.42%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRAX vs. MTEX, EDSA, FLGC, ATHA, ALLR, PMN, SNPX, LEXX, NEUP, and HOOK

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Mannatech (MTEX), Edesa Biotech (EDSA), Flora Growth (FLGC), Athira Pharma (ATHA), Allarity Therapeutics (ALLR), Promis Neurosciences (PMN), Synaptogenix (SNPX), Lexaria Bioscience (LEXX), Neuphoria Therapeutics (NEUP), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry.

Virax Biolabs Group vs. Its Competitors

Mannatech (NASDAQ:MTEX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Mannatech has higher revenue and earnings than Virax Biolabs Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$117.87M0.13$2.49M-$0.10-78.30
Virax Biolabs Group$10K416.90-$6.06MN/AN/A

Mannatech has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Virax Biolabs Group has a consensus target price of $3.00, indicating a potential upside of 212.30%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Mannatech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Virax Biolabs Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Mannatech. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Mannatech. Virax Biolabs Group's average media sentiment score of 1.89 beat Mannatech's score of 1.87 indicating that Virax Biolabs Group is being referred to more favorably in the news media.

Company Overall Sentiment
Mannatech Very Positive
Virax Biolabs Group Very Positive

Virax Biolabs Group has a net margin of 0.00% compared to Mannatech's net margin of -0.19%. Virax Biolabs Group's return on equity of 0.00% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-0.19% -2.56% -0.57%
Virax Biolabs Group N/A N/A N/A

Summary

Virax Biolabs Group beats Mannatech on 11 of the 14 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRAX vs. The Competition

MetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.17M$2.91B$5.52B$9.41B
Dividend YieldN/A2.45%3.80%4.04%
P/E RatioN/A19.8828.0419.84
Price / Sales416.90305.11429.5399.59
Price / CashN/A43.1635.8457.94
Price / Book0.767.678.125.65
Net Income-$6.06M-$55.28M$3.25B$258.00M
7 Day Performance6.73%2.50%0.97%2.09%
1 Month Performance18.45%11.70%7.36%11.13%
1 Year Performance-16.47%4.89%31.31%18.40%

Virax Biolabs Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRAX
Virax Biolabs Group
3.1336 of 5 stars
$0.96
+4.4%
$3.00
+212.3%
-25.2%$3.99M$10K0.005News Coverage
Positive News
Gap Up
MTEX
Mannatech
1.227 of 5 stars
$8.20
-3.5%
N/A+12.3%$15.58M$117.87M-81.99250Positive News
EDSA
Edesa Biotech
2.2088 of 5 stars
$2.19
-0.6%
$5.00
+128.7%
-49.5%$15.37MN/A-1.3820Positive News
Gap Up
FLGC
Flora Growth
2.5108 of 5 stars
$0.68
-1.9%
$4.00
+491.7%
-42.6%$15.35M$53.26M-0.69280Positive News
ATHA
Athira Pharma
3.7754 of 5 stars
$0.39
-2.3%
$11.25
+2,762.6%
-88.4%$15.34MN/A-0.1940Positive News
Gap Up
ALLR
Allarity Therapeutics
0.6576 of 5 stars
$1.01
-3.8%
N/A-83.7%$15.16MN/A0.0010Positive News
PMN
Promis Neurosciences
3.1605 of 5 stars
$0.45
-14.4%
$4.33
+873.8%
-78.1%$14.61MN/A-8.945News Coverage
Analyst Revision
Gap Up
High Trading Volume
SNPX
Synaptogenix
0.2484 of 5 stars
$10.38
+15.5%
N/A+107.8%$14.43MN/A-1.034Positive News
Gap Up
High Trading Volume
LEXX
Lexaria Bioscience
1.9581 of 5 stars
$0.81
-2.4%
$5.00
+514.3%
-69.8%$14.29M$460K-1.387Earnings Report
NEUP
Neuphoria Therapeutics
1.8924 of 5 stars
$7.58
-1.6%
$21.00
+177.0%
N/A$14.25M$15.66M0.00N/ANews Coverage
Positive News
HOOK
HOOKIPA Pharma
3.2316 of 5 stars
$1.17
-2.9%
$4.50
+286.3%
-82.4%$14.20M$43.95M-0.20160News Coverage
Positive News
Trading Halted

Related Companies and Tools


This page (NASDAQ:VRAX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners